The Office of the U.S. Trade Representative (USTR) announced the extension of exclusions for numerous COVID-19 products that are subject to China Section 301 tariffs. The exclusions originally scheduled to expire on November 30, 2022, have been extended until February 28, 2023. The exclusions cover 81 medical care products and were initially granted in December 2020.
Although the reinstated exclusions are set to end in February 2023, USTR remains open to “further extensions, as appropriate.” The agency, however, would likely prefer to maintain flexibility to adjust.
If you have any questions about how USTR’s action may impact your imports or Section 301 litigation, please Contact Us anytime.